ClinicalTrials.gg
Sign In

Drug

Ruzaltatug rezetecan clinical trials

studies test it
8
open now
5
in phase 3
1
first study started
2022

Keep track of what changes. Save the ruzaltatug rezetecan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

SHR-A2009
5

Combined with it in one product

SHR-A2009 ; Aumolertinib
1
adebrelimab + SHR-A2009
1
SHR-A2009; SHR-1316
1

Studies by the year they started

8 studies that test it; most in 2022 (3)

Studies that test ruzaltatug rezetecan, by start year
YearStudies
20223
20243
20251
20261

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
5
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it.

Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Neoplasms
1
Triple Negative Breast Neoplasms
1

Who runs them

Industry 5 · Other 3

Suzhou Suncadia Biopharmaceuticals Co., Ltd. (4) · Fudan University (2) · Henan Cancer Hospital (1) · Shandong Suncadia Medicine Co., Ltd. (1)

Often tested with

Tested in the same studies.

Tizetatug rezetecan (3) · Aumolertinib (2) · Adebrelimab (2) · Trastuzumab rezetecan (2) · Notiretatug rezetecan (2) · Famitinib (2) · Trastuzumab (1) · Bulumtatug fuvedotin (1)

Studies

Open first, then newest update. How each study uses ruzaltatug rezetecan is read from its arms, and is right about nine times in ten.

Testing it · 8

Given in every arm · 2 — ruzaltatug rezetecan is usual care beside what is tested

Codes

What other systems call ruzaltatug rezetecan · ClinicalTrials.gg INT017732

  • UNII (FDA) QZA4R4JG2ZRUZALTATUG REZETECANOne source FDA
  • NCI Thesaurus C202278Ruzaltatug RezetecanOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.